Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Synbiotics in the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications (CROSBI ID 320552)

Prilog u časopisu | stručni rad | međunarodna recenzija

(Working Group on Probiotics and Prebiotics of the European Society for Paediatric Gastroenterology ; Hepatology and Nutrition ;) Hojsak, Iva ; Kolaček, Sanja ; Mihatsch, Walter ; Mosca, Alexis ; Shamir, Raanan ; Szajewska, Hania ; Vandenplas, Yvan Synbiotics in the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications // Journal of pediatric gastroenterology and nutrition, 76 (2022), 1; 102-108. doi: 10.1097/mpg.0000000000003568

Podaci o odgovornosti

Hojsak, Iva ; Kolaček, Sanja ; Mihatsch, Walter ; Mosca, Alexis ; Shamir, Raanan ; Szajewska, Hania ; Vandenplas, Yvan

Working Group on Probiotics and Prebiotics of the European Society for Paediatric Gastroenterology ; Hepatology and Nutrition ;

engleski

Synbiotics in the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications

Background: Synbiotics are a mixture comprising of live microorganisms and substrate(s) selectively utilized by host microorganisms that confers a health benefit on the host. There is an increasing number of studies investigating their role in different diseases and disorders. Aim: The purpose of this article is to provide recommendations for the use of synbiotics in the management of pediatric gastrointestinal disorders. The recommendations are developed by the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. Methods: From existing literature databases, we searched and appraised all systematic reviews and/or meta-analyses, and subsequently published randomized controlled trials (RCTs) that compared the use of synbiotics, in all delivery vehicles and formulations, at any dose, compared to no synbiotics. Synbiotics which are part of infant formula were not assessed. The recommendations were formulated only if at least 2 RCTs that used a well-defined synbiotic were available. Results: Based on the currently available evidence, no recommendation can be formulated in favor or against the use of evaluated synbiotic combination in the treatment of acute gastroenteritis, prevention of necrotizing enterocolitis, Helicobacter pylori infection, inflammatory bowel disease, functional gastrointestinal disorders, and allergy in infants and children. Conclusions: There is a need for more, well- designed RCTs on the role of synbiotics in gastrointestinal disorders with the same outcome measures to enable the inter-studies comparisons.

synbiotics

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

76 (1)

2022.

102-108

objavljeno

0277-2116

1536-4801

10.1097/mpg.0000000000003568

Povezanost rada

nije evidentirano

Poveznice
Indeksiranost